TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00020189
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020189
Drug: clopidogrel bisulfate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01672723
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00649662
Drug: Ciprofloxacin Extended-Release Tablets 1000 mg
Normalized name: ciprofloxacin Extended Release Oral Tablet
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg, single dose fasting
Study: NCT00861978
Drug: St. John's Wort extract
Normalized name: St. John's wort extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
Study: NCT02059915
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
Study: NCT02059915
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
Study: NCT02059915
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
Study: NCT02059915
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
Study: NCT04288765
Drug: Daratumumab Only Product in Parenteral Dose Form
Normalized name: Daratumumab only product in parenteral dose form
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly
Study: NCT00002521
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002521
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01041170
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01041170
Drug: Rimonobant
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01041170
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02080312
Drug: Magnevist (gadopentetate dimeglumine)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00435591
Drug: Conivaptan
Normalized name: Conivaptan
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ampoule or premix bag
Study: NCT00210470
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 days of 20 mg. orally
Study: NCT01008293
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
Study: NCT01621113
Drug: Dalfampridine
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
Study: NCT01614197
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
Study: NCT01614197
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
Study: NCT01614197
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~* Age 1 - 1.99 give 30 mg of Cytarabine~* Age 2 - 2.99 give 50mg of Cytarabine~* Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~* 16 mg for patients age 1-1.99~* 20 mg for patients age 2-2.99~* 24 mg for patients 3-8.99 years of age~* 30 mg for patients \>9 years of age
Study: NCT00948142
Drug: CEM-102
Normalized name: CEM-Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BID oral tablets for 10-14 days
Study: NCT00948142
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg BID oral tablets
Study: NCT00948142
Drug: CEM-102
Normalized name: CEM-Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
Study: NCT01476774
Drug: Buprenorphine Transdermal System
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .
Study: NCT03159143
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.
Study: NCT03159143
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
Study: NCT00451880
Drug: XL281
Normalized name: XL281
DrugBank: XL281 (DB05190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
Study: NCT00451880
Drug: famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose, supplied as 20-mg or 40-mg tablets
Study: NCT00744939
Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
Study: NCT03151369
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients with the visual analog scale over 3 will receive morphine
Study: NCT02744716
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose of Aspirin after operation
Study: NCT02532400
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
Study: NCT01649765
Drug: belimumab 10mg/kg
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10mg/kg IV monthly
Study: NCT02188550
Drug: everolimus and letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally
Study: NCT00927407
Drug: Malathion gel 0.5%
DrugBank: Malathion (DB00772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Malathion gel 0.5% applied to the scalp for 30 minutes
Study: NCT00927407
Drug: Malathion lotion 0.5%
DrugBank: Malathion (DB00772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Malathion lotion 0.5% applied to scalp for 12 hours
Study: NCT01739335
Drug: Mifepristone Oral Tablet [Korlym]
Normalized name: mifepristone Oral Tablet [Korlym]
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
Study: NCT00499122
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00499122
Drug: NOV 002
Normalized name: NOV-002
DrugBank: NOV-002 (DB05393)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00383136
Drug: tirofiban high-bolus dose regimen
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
Study: NCT00383136
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
Study: NCT01217957
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsules
Study: NCT01217957
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide capsules
Study: NCT01217957
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets
Study: NCT01640054
Drug: Fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib 100mg once daily
Study: NCT01086488
Drug: FOSCAN
DrugBank: Temoporfin (DB11630)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
Study: NCT00118755
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m\^2 IV on Day 1 of each 3-week cycle
Study: NCT00118755
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg IV on Day 1 of each 3-week cycle
Study: NCT00118755
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m\^2 IV on Day 1 of each 2-week cycle
Study: NCT00118755
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg IV on Day 1 of each 2-week cycle
Study: NCT03005860
Drug: 2,6-Diisopropylphenol
Normalized name: 2,6-Diisopropylphenol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
Study: NCT03005860
Drug: Fluoromethyl hexafluoroisopropyl ether
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
Study: NCT03650738
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
Study: NCT03005860
Drug: Atracurium Besylate
Normalized name: Atracurium Besylate
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
Study: NCT02486133
Drug: Prezista
Normalized name: Prezista
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once daily
Study: NCT02486133
Drug: Norvir
Normalized name: Norvir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once daily
Study: NCT02486133
Drug: Tivicay
Normalized name: Tivicay
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once daily
Study: NCT02486133
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily
Study: NCT02486133
Drug: Kivexa
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once daily
Study: NCT02486133
Drug: Descovy
Normalized name: Descovy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once daily
Study: NCT04012138
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
Study: NCT04012138
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol.
Study: NCT02613130
Drug: Stannous fluoride toothpaste
Normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02613130
Drug: Potassium nitrate toothpaste
Normalized name: potassium nitrate Toothpaste
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01130844
Drug: MMX Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Study: NCT01130844
Drug: MMX Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Study: NCT01130844
Drug: MMX Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Study: NCT00546403
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive treatment with titrated dose of modafinil
Study: NCT03057574
Drug: Follitropin Alfa
Normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients must be prescribed Follitropin Alfa (Gonapure®)
Study: NCT04559880
Drug: Tranexamic Acid Injection [Cyklokapron]
Normalized name: tranexamic acid Injection [Cyklokapron]
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
Study: NCT02931071
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF (12 μg/Kg/12 h) 8 days.
Study: NCT02931071
Drug: plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
Study: NCT03214094
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan tablets
Study: NCT01248416
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01248416
Drug: Aromatase Inhibitor and Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01771328
Drug: Cortisone acetate
Normalized name: Cortisone Acetate
DrugBank: Cortisone acetate (DB01380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
Study: NCT03098420
Drug: 2mg Dexamethasone
Normalized name: dexamethasone 2 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
Study: NCT03098420
Drug: 4mg Dexamethasone
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mL (4mg) of dexamethasone
Study: NCT03098420
Drug: Ropivacaine (TAP blocks)
Normalized name: Ivy Block
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
Study: NCT03098420
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03098420
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03098420
Drug: Normal saline 1ml
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
Study: NCT02521311
Drug: Clemastine
Normalized name: Clemastine
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
Study: NCT03618823
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT00054054
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00054054
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01131234
Drug: Cediranib Maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01785641
Drug: ceftazidime+ciprofloxacin
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
Study: NCT01785641
Drug: ceftazidime monotherapy
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ceftazidime IP for gram negative bacterial peritonitis
Study: NCT01785641
Drug: cefazolin monotherapy
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefazolin IP for gram positive bacterial peritonitis
Study: NCT00723827
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of temozolomide based on the product labeling.
Study: NCT01674725
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT04126525
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dual HER2 blockade in the neoadjuvant setting
Study: NCT04004208
Drug: Eylea (Aflibercept, BAY86-5321)
Normalized name: Eylea
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution in a sterile glass vial, Dose A, IVT injection.
Study: NCT03847168
Drug: KN026
Normalized name: ANTI-HER2 BSAB KN026
DrugBank: Anbenitamab (DB18411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be intravenously administrated with one dose of KN026 every week or every other week.
Study: NCT01515956
Drug: BMN 110
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
Study: NCT00309816
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no